On the Record · Biogen
Biogen competitors, on the record
The companies Biogen names as competitors in its annual reports, 2023 to 2025, and the companies that name Biogen, each with the sentence and the filing.
Who Biogen names
| Company | Named in |
|---|---|
| Eli Lilly and Company | 2025 |
In its own words
Eli Lilly and Company
Word for word“A competing product, KISUNLA, a treatment for early symptomatic Alzheimer's disease that was developed by Eli Lilly and Company, was approved in the U.S. in 2024 and in the E.U. in 2025.” 10-K for 2025
Who names Biogen
Companies whose own annual reports name Biogen as a competitor.
Word for word“If approved, vatiquinone could face competition from Skyclarys (omaveloxolone) from Biogen, which is approved in the United States and the EU.” 10-K for 2025
Read from Biogen’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-06. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.